Skip to content

Objectives

The project runs on four tracks, from proving the mechanism to eventually correcting it. Each has a concrete near-term deliverable.

1. Establish the phenotype in the literature

There is, as of this writing, no published case report of the heterozygous (single-copy) SAMHD1 p.A565T phenotype. The biallelic form is known (Aicardi-Goutières syndrome), but the heterozygous carrier state has no described natural history. The first objective is to fix that.

  • Deliverable: a case report / small case series suitable for a peer-reviewed venue, built from the five-generation kindred.
  • Why it matters: publication is what lets other clinicians recognize the pattern in their own patients and turns an n of one family into a defined condition.

2. Confirm the mechanism

Move the three-arm model from framework to evidence:

  • Interferon signature (ISG score) across the kindred, including the subclinical carrier and the eldest and youngest members, to anchor the natural-history span.
  • Primary-cell confirmation of the nucleotide/NLRP3 metabolic arm in carrier-derived cells (the current gap — most direct evidence is from knockout systems, not heterozygous cells).
  • Structural modeling to resolve the haploinsufficiency vs. dominant-negative question at the C-terminal latch — the answer directly shapes any gene-correction strategy.

3. Treat what is treatable now

The model makes a sharp, testable clinical prediction: JAK inhibition should resolve the interferon-driven arm nearly completely while leaving a JAK-resistant metabolic/energetic floor. Observed single-patient response is consistent with this. The therapeutic objective is a rational, mechanism-matched regimen:

  • JAK inhibition for the interferon arm.
  • Upstream targeting of the nucleotide/NLRP3 arm (the JAK-resistant floor) — e.g., inflammasome- or nucleotide-directed strategies.
  • A structured multi-arm study design that tests these arms against the specific mechanisms they are meant to hit, with predefined biomarkers.

4. Open a path to correction

For a rare single-nucleotide missense variant, the long-horizon goal is precise gene correction — repairing the single base change rather than managing its downstream consequences for life. This is why the weekly research surveillance (the blog) tracks advances in prime editing, base editing, and delivery to immune and blood-forming cells alongside the disease biology: the therapy and the delivery vehicle are moving targets worth watching now, even though clinical application is years out.

How the automation serves the objectives

This is a small, patient-led effort, so leverage comes from automation:

  • A weekly semantic literature sweep scores every new relevant paper against this exact phenotype and publishes the digest to the research blog.
  • A monthly synthesis summarizes what moved.
  • A privacy guard ensures nothing identifying ever leaves the private working repository for this public site.

The result is that a single family can maintain research-grade situational awareness of a fast-moving field — and share it openly.